Sublingual Nitrates for Patients as a Default in the Post-ACS Discharge Pack: Is It Time for a Rethink?

Circulation. 2022 Mar 15;145(11):791-792. doi: 10.1161/CIRCULATIONAHA.121.058008. Epub 2022 Mar 14.

Authors

Avedis A Ekmejian¹, Ravinay Bhindi^{1

2}, Gemma A Figtree^{1

2

3}

Affiliations

¹ Department of Cardiology, Royal North Shore Hospital, Sydney, Australia (A.A.E., R.B., G.A.F.).
² Cardiovascular Discovery Group, Kolling Institute of Medical Research (R.B., G.A.F.), University of Sydney, Australia.
³ Charles Perkins Centre (G.A.F.), University of Sydney, Australia.

PMID: 35286167
DOI: 10.1161/CIRCULATIONAHA.121.058008

No abstract available

Keywords: cost-benefit analysis; harm reduction; myocardial infarction; nitroglycerin.

MeSH terms

Administration, Sublingual
Humans
Nitrates*
Nitroglycerin
Patient Discharge*
Vasodilator Agents / therapeutic use

Substances

Nitrates
Vasodilator Agents
Nitroglycerin